These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 23389810)

  • 1. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis.
    Wong GL; Chan HL; Mak CW; Lee SK; Ip ZM; Lam AT; Iu HW; Leung JM; Lai JW; Lo AO; Chan HY; Wong VW
    Hepatology; 2013 Nov; 58(5):1537-47. PubMed ID: 23389810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
    Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
    Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis.
    Kim SS; Hwang JC; Lim SG; Ahn SJ; Cheong JY; Cho SW
    Am J Gastroenterol; 2014 Aug; 109(8):1223-33. PubMed ID: 24890440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma.
    Jin YJ; Shim JH; Lee HC; Yoo DJ; Kim KM; Lim YS; Suh DJ
    J Gastroenterol Hepatol; 2011 Sep; 26(9):1380-8. PubMed ID: 21884247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis.
    Zoutendijk R; Reijnders JG; Zoulim F; Brown A; Mutimer DJ; Deterding K; Hofmann WP; Petersen J; Fasano M; Buti M; Berg T; Hansen BE; Sonneveld MJ; Wedemeyer H; Janssen HL;
    Gut; 2013 May; 62(5):760-5. PubMed ID: 22490523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants.
    Yang SC; Lee CM; Hu TH; Wang JH; Lu SN; Hung CH; Changchien CS; Chen CH
    J Antimicrob Chemother; 2013 Sep; 68(9):2154-63. PubMed ID: 23620466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine.
    Lim YS; Han S; Heo NY; Shim JH; Lee HC; Suh DJ
    Gastroenterology; 2014 Jul; 147(1):152-61. PubMed ID: 24583062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea.
    Park YH; Kim BK; Kim JK; Kim HC; Kim DY; Park JY; Han KH; Kim SU; Shin SH; Hahn KY; Ahn SH
    J Gastroenterol Hepatol; 2014 May; 29(5):1005-11. PubMed ID: 24325579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort.
    Papatheodoridis GV; Manolakopoulos S; Touloumi G; Nikolopoulou G; Raptopoulou-Gigi M; Gogos C; Vafiadis-Zouboulis I; Karamanolis D; Chouta A; Ilias A; Drakoulis C; Mimidis K; Ketikoglou I; Manesis E; Mela M; Hatzis G; Dalekos GN;
    J Viral Hepat; 2015 Feb; 22(2):120-7. PubMed ID: 25040685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B.
    Lee J; Yoo SH; Sohn W; Kim HW; Choi YS; Won JH; Heo JY; Park SJ; Park YM
    Clin Mol Hepatol; 2016 Sep; 22(3):339-349. PubMed ID: 27729627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting.
    Idilman R; Gunsar F; Koruk M; Keskin O; Meral CE; Gulsen M; Elhan AH; Akarca US; Yurdaydin C
    J Viral Hepat; 2015 May; 22(5):504-10. PubMed ID: 25431108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong.
    Lee KK; Wu DB; Chow PY; Lee VW; Li H
    J Gastroenterol Hepatol; 2012 Jul; 27(7):1167-74. PubMed ID: 22141402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment.
    Wong GL; Chan HL; Chan HY; Tse PC; Tse YK; Mak CW; Lee SK; Ip ZM; Lam AT; Iu HW; Leung JM; Wong VW
    Gastroenterology; 2013 May; 144(5):933-44. PubMed ID: 23415803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Entecavir versus lamivudine in the treatment of chronic hepatitis B patients with hepatic decompensation.
    Hsu YC; Mo LR; Chang CY; Perng DS; Tseng CH; Lo GH; Tai CM; Lin CW; Hsu CC; Hsu CY; Huang SC; Lin JT
    Antivir Ther; 2012; 17(4):605-12. PubMed ID: 22301517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation.
    Fung J; Cheung C; Chan SC; Yuen MF; Chok KS; Sharr W; Dai WC; Chan AC; Cheung TT; Tsang S; Lam B; Lai CL; Lo CM
    Gastroenterology; 2011 Oct; 141(4):1212-9. PubMed ID: 21762659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study.
    Choi J; Kim HJ; Lee J; Cho S; Ko MJ; Lim YS
    JAMA Oncol; 2019 Jan; 5(1):30-36. PubMed ID: 30267080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and virological response to entecavir in HBV-related chronic hepatitis or cirrhosis: data from the clinical practice in a single-centre cohort.
    Marengo A; Bitetto D; D'Avolio A; Ciancio A; Fabris C; Marietti M; Toniutto P; Di Perri G; Rizzetto M; Marzano A
    Antivir Ther; 2013; 18(1):87-94. PubMed ID: 22872649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection.
    Hosaka T; Suzuki F; Kobayashi M; Seko Y; Kawamura Y; Sezaki H; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    Hepatology; 2013 Jul; 58(1):98-107. PubMed ID: 23213040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match-control study.
    Tsai MC; Chen CH; Hung CH; Lee CM; Chiu KW; Wang JH; Lu SN; Tseng PL; Chang KC; Yen YH; Hu TH
    Clin Microbiol Infect; 2014 Feb; 20(2):O90-O100. PubMed ID: 23659493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis.
    Liu K; Choi J; Le A; Yip TC; Wong VW; Chan SL; Chan HL; Nguyen MH; Lim YS; Wong GL
    Aliment Pharmacol Ther; 2019 Nov; 50(9):1037-1048. PubMed ID: 31524304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.